The baseline is completely broken and the iteration process is blind.
FDA’s August 21, 2026 warning letter to Pensar Medical LLC illustrates a failure that goes well beyond incomplete documentation.
The underlying risk-management foundation was weak. Risk-control verification remained incomplete for critical areas, and FDA reportedly found no design, process, or use-related FMEAs for the WoundPro product line.
At the same time, key QMS processes were also failing.
Key highlights covered in the audio:
* Risk analysis was incomplete or missing. Critical risk controls remained unverified, and some products lacked the basic FMEAs required by the firm’s own procedures.
* Design and software changes were poorly controlled. Multiple changes lacked adequate implementation records, including an engineering change order described simply as “clean up all code,” with no verification record showing what had actually changed.
* Field corrections were not properly managed. Software rework performed in the field was not reported within the required timeframe.
* CAPA was not functioning as a learning system. FDA found CAPA records with missing root-cause analysis, corrective actions, and effectiveness verification. In another case, a corrective action was never incorporated back into the risk analysis.
* Post-market information was not being translated into effective action. A serious injury involving retained foam and surgical intervention was reported late and categorized as a malfunction rather than a serious injury.
The central lesson is straightforward:
A robust QMS needs both a reliable risk baseline and processes that continuously challenge, maintain, and improve that baseline.
If the original risk analysis is weak, changes cannot be evaluated properly. If CAPA, complaint handling, change control, and post-market processes are weak, new information never strengthens the risk analysis.
That is how individual weaknesses become a systemic quality failure..
Keywords:
Pensar Medical, FDA Warning Letter, QMSR, ISO 13485, Risk Management, Risk Analysis, Design Change Control, CAPA, Medical Device Reporting, Quality Management System
🎧Listen to the Deep Dive for a closer look at how the Pensar warning letter shows the consequences when both risk management and the broader QMS fail to operate as a closed-loop system.
Thanks for reading Let's Talk Risk!. If you liked this post, share with others.
Note:
The audio summary was prepared using Google NotebookLM, an AI-enabled research tool. Here are a few key resources used for this analysis:
* FDA (2026). Warning Letter: Lion Street Medical, d/b/a Pensar Medical LLC (CDRH-MARCS-CMS 733015).
This is a public episode. If you'd like to discuss this with other subscribers or get access to bonus episodes, visit naveenagarwalphd.substack.com/subscribe
